Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) reached a new 52-week low on Monday . The company traded as low as $10.57 and last traded at $10.61, with a volume of 98023 shares trading hands. The stock had previously closed at $11.78.
Wall Street Analysts Forecast Growth
DNLI has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft assumed coverage on Denali Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $31.00 target price for the company. Robert W. Baird began coverage on Denali Therapeutics in a report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 target price for the company. JPMorgan Chase & Co. cut their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 7th. The Goldman Sachs Group reduced their target price on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Finally, B. Riley restated a "buy" rating and issued a $35.00 target price (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. One analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $37.57.
Check Out Our Latest Stock Report on Denali Therapeutics
Denali Therapeutics Price Performance
The business's 50 day simple moving average is $16.53 and its 200 day simple moving average is $21.83. The company has a market capitalization of $1.84 billion, a PE ratio of -4.60 and a beta of 1.58.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.08. As a group, analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.
Hedge Funds Weigh In On Denali Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of DNLI. Vanguard Group Inc. boosted its position in shares of Denali Therapeutics by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock worth $244,993,000 after acquiring an additional 843,996 shares in the last quarter. FMR LLC boosted its holdings in Denali Therapeutics by 2.4% in the fourth quarter. FMR LLC now owns 8,019,746 shares of the company's stock valued at $163,442,000 after purchasing an additional 188,368 shares in the last quarter. Alliancebernstein L.P. increased its stake in Denali Therapeutics by 8.8% in the fourth quarter. Alliancebernstein L.P. now owns 3,315,642 shares of the company's stock valued at $67,573,000 after purchasing an additional 268,378 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Denali Therapeutics by 6.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,058,615 shares of the company's stock worth $62,335,000 after purchasing an additional 188,820 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Denali Therapeutics by 19.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company's stock worth $37,805,000 after purchasing an additional 295,594 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.
Denali Therapeutics Company Profile
(
Get Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Read More
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
